Rahko’s Co-founder and former VP of AI at Odyssey Therapeutics will lead the technical growth of LabGenius’ ML-driven drug discovery platform LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use ...
LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use of machine learning (ML) for protein engineering, today announced the signing of a multi-year research collaboration with Ablynx, a Sanofi ...
For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA™,was used to discover and concomitantly optimise a TCE with improved killing ...
Prominent oncology clinician Prof Hendrik-Tobias Arkenau and computational antibody design expert Prof Victor Greiff will bolster LabGenius’ leadership in the field of machine learning-driven antibody ...
LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) Annual 2023 Meeting ...
LabGenius Therapeutics (“LabGenius”) is a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimize complex therapeutic antibodies, including those with ...
Multi-year collaboration where LabGenius will apply its ML-driven protein engineering platform, EVA TM, to the optimization of therapeutic NANOBODY ® proteins LONDON–(BUSINESS WIRE)–July 15, 2021– ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results